Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nuevolution A/S currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is distributed across 1 distinct examiner and 1 distinct art unit. The involvement of 1 distinct art unit indicates the technological scope of the company's current patent applications. Practitioners should note that the pending workload is handled by 1 distinct examiner, which defines the coordination of prosecution strategies across the portfolio.
MARTIN, KEVIN STEPHEN is identified as the busiest examiner for Nuevolution A/S, currently overseeing 1 pending office action. As MARTIN, KEVIN STEPHEN is responsible for 1 pending office action, this individual represents a point of contact for the company's interactions with the patent office. The distribution of the workload among the 1 distinct examiner indicates how the company's Biotechnology & Pharmaceuticals filings are being processed. Practitioners should monitor the 1 distinct art unit for updates on the pending prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.4% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860589 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | MARTIN, KEVIN STEPHEN | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860589 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | MARTIN, KEVIN STEPHEN | 1629 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuevolution A/S has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kevin Stephen Martin has the most, with 1 of Nuevolution A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.